“Retirement Secret” Showed 995% Gain Last Time We Shared It

See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)

Josep Bassaganya-Riera net worth and biography

Josep Bassaganya-Riera Biography and Net Worth

Major Shareholder of Landos Biopharma

Josep Bassaganya-Riera has served as the Chairman of the Board, President and CEO of Landos Biopharma (NASDAQ: LABP) since Landos’ founding in January 2017. He previously served as the CEO at Biotherapeutics and founded the NIMML Institute. He has published over 200 peer-reviewed articles, book chapters and books on A.I., modeling-driven drug design and computational immunology, and he has contributed 190 patents in immunology, inflammation and autoimmune disease treatment.
He has founded several award-winning Companies, raising over $800 million in non-dilutive and equity financing rounds. Through his entrepreneurial corporate mindset, encapsulated in four pillars: be bold and decisive, never give up, be solution-oriented and do the impossible, Dr. Bassaganya-Riera empowers employees to think outside the box to achieve innovative solutions that promote innovation, excellence, efficiency, and creativity. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a PhD in Nutritional Immunology from Iowa State University.

How old is Josep Bassaganya-Riera?: Dr. Bassaganya-Riera is currently 49 years old. There are 1 older executives and no younger executives at Landos Biopharma. The oldest executive at Landos Biopharma is Ms. Jennifer Creel, Interim Chief Financial Officer, who is 53 years old. Learn More on Josep Bassaganya-Riera's age.
How do I contact Josep Bassaganya-Riera?: The corporate mailing address for Dr. Bassaganya-Riera and other Landos Biopharma executives is 1800 KRAFT DRIVE SUITE 216, BLACKSBURG VA, 24060. Landos Biopharma can also be reached via phone at 540-218-2232 and via email at [email protected]. Learn More on Josep Bassaganya-Riera's contact information.
Has Josep Bassaganya-Riera been buying or selling shares of Landos Biopharma?: Josep Bassaganya-Riera has not been actively trading shares of Landos Biopharma in the last ninety days. Most recently, Josep Bassaganya-Riera sold 3,319 shares of the business's stock in a transaction on Monday, December 20th. The shares were sold at an average price of $47.50, for a transaction totalling $157,652.50. Learn More on Josep Bassaganya-Riera's trading history.

Josep Bassaganya-Riera Insider Trading History at Landos Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/20/2021	Sell	3,319	$47.50	$157,652.50
12/17/2021	Sell	3,600	$48.40	$174,240.00
12/15/2021	Sell	4,300	$50.20	$215,860.00
12/13/2021	Sell	4,000	$53.70	$214,800.00
12/10/2021	Sell	4,000	$57.70	$230,800.00
12/8/2021	Sell	2,553	$66.50	$169,774.50
12/6/2021	Sell	3,600	$61.70	$222,120.00
12/3/2021	Sell	3,600	$61.50	$221,400.00
12/1/2021	Sell	3,223	$70.10	$225,932.30
11/29/2021	Sell	1,543	$75.80	$116,959.40

Josep Bassaganya-Riera Buying and Selling Activity at Landos Biopharma

Landos Biopharma Company Overview

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Today's Range

Now: $22.49

$22.21

$22.84

50 Day Range

MA: $13.40

$5.46

$22.36

2 Week Range

Now: $22.49

$2.50

$22.84

Volume

3,500 shs

Average Volume

21,821 shs

Market Capitalization

$70.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14